使用 lisocabtagene maraleucel 的 CAR-T 细胞治疗成功用于一例伴复发/难治性弥漫大 B 细胞淋巴瘤（DLBCL）的肾移植受者

This case describes a 53-year-old male with end-stage renal disease who developed monomorphic post-transplant lymphoproliferative disorder (PTLD) in the form of diffuse large B-cell lymphoma (DLBCL) after kidney transplantation. Despite initial treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP), the patient's disease progressed, and he was referred for chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel (liso-cel).

Given his post-transplant status, his immunosuppressive agents (tacrolimus and mycophenolate) were held, and prednisone was tapered to 5 mg daily to maintain minimal baseline immunosuppression. After lymphodepleting chemotherapy and liso-cel infusion, the patient experienced no significant toxicities, including cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).

This case underscores the potential of CAR-T therapy for refractory/relapsed DLBCL in post-transplant patients, emphasizing the need for careful immunosuppressive management to balance graft protection and treatment efficacy.